The U.S. Food and Drug Administration issued draft guidance designed to simplify biosimilar development by allowing, in certain cases, reliance on comparator product data generated outside the U.S. and reduced clinical testing requirements. The agency says the shift could halve development costs and accelerate competition for high‑priced biologics. Regulators framed the guidance as a way to expand patient access and reduce healthcare spending, particularly in oncology and chronic inflammatory diseases where biologics dominate costs. Industry and biosimilar developers welcome potential savings, but originator companies and some stakeholders will scrutinize interchangeability, analytical comparability standards, and the guidance’s impact on global development strategies.